Drug Type Monoclonal antibody |
Synonyms 重组人源化抗表皮生长因子受体单克隆抗体 (津曼特生物), JMT 101, JMT-101 + [1] |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 3 | China | 23 Oct 2024 | |
EGFR positive Non-squamous non-small cell lung cancer | Phase 3 | China | 17 Oct 2024 | |
Squamous non-small cell lung cancer | Phase 3 | - | 01 May 2024 | |
EGFR ex20ins mutation in non-small cell lung cancer | Phase 3 | China | 28 Apr 2024 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 3 | - | 26 Apr 2024 | |
Non-small cell carcinoma | Phase 3 | China | - | |
Nasopharyngeal Neoplasms | Phase 2 | - | 01 Apr 2025 | |
Nasopharyngeal Carcinoma | Phase 2 | China | 25 Mar 2025 | |
Metastatic Colorectal Carcinoma | Phase 2 | China | 24 Nov 2023 | |
metastatic non-small cell lung cancer | Phase 2 | China | 21 Nov 2021 |
Phase 2 | EGFR-mutated non-small Cell Lung Cancer EGFR Mutation | 161 | (treatment naïve pts) | qssscbkkcz(qnwcywhsuy) = xcucllaalf mzicvkkoki (tuvehuuwxi, 61.1 - 91.0) View more | Positive | 12 Dec 2024 | |
(pts resistant to 1st or 2nd generation EGFR-TKI therapy and without T790M mutation) | qssscbkkcz(qnwcywhsuy) = rqwanswgxm mzicvkkoki (tuvehuuwxi, 3.2 - 37.9) View more | ||||||
Phase 2 | Non-Small Cell Lung Cancer EGFR Exon 20 Insertion | 126 | judwkzjlry(fxxjfdskuc) = ajbdhyidly xjlalqvdmd (rrdxvcfxxn, 40 - 60) View more | Positive | 20 Mar 2024 | ||
Phase 1 | 23 | stqpkndhov(wybhhaudfb) = 86.0% [6/7] in combination group pqkmrwoing (wxkveyfckx ) View more | Positive | 25 May 2020 | |||